These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 38443664)
21. Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness. Priyanka ; Choudhary OP; Singh I Travel Med Infect Dis; 2021; 40():101983. PubMed ID: 33548551 [No Abstract] [Full Text] [Related]
22. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448 [TBL] [Abstract][Full Text] [Related]
23. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513 [TBL] [Abstract][Full Text] [Related]
25. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425 [TBL] [Abstract][Full Text] [Related]
26. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Yang R; Deng Y; Huang B; Huang L; Lin A; Li Y; Wang W; Liu J; Lu S; Zhan Z; Wang Y; A R; Wang W; Niu P; Zhao L; Li S; Ma X; Zhang L; Zhang Y; Yao W; Liang X; Zhao J; Liu Z; Peng X; Li H; Tan W Signal Transduct Target Ther; 2021 May; 6(1):213. PubMed ID: 34059617 [TBL] [Abstract][Full Text] [Related]
27. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
30. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121 [No Abstract] [Full Text] [Related]
31. A network analysis of COVID-19 mRNA vaccine patents. Gaviria M; Kilic B Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074 [No Abstract] [Full Text] [Related]
32. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R; Yip L; Ahn SK; Chau S; Naghibosadat M; Arita Y; Hu Q; Yue FY; Banerjee A; Hardy WR; Mossman K; Mubareka S; Kozak RA; Pollanen MS; Martin Orozco N; Gingras AC; Marcusson EG; Ostrowski MA Sci Adv; 2022 Jan; 8(3):eabj9815. PubMed ID: 35044832 [TBL] [Abstract][Full Text] [Related]
33. When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. Moussatché N; Damaso CR; McFadden G J Infect Dev Ctries; 2008 Jun; 2(3):156-73. PubMed ID: 19738346 [TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Turner JS; O'Halloran JA; Kalaidina E; Kim W; Schmitz AJ; Zhou JQ; Lei T; Thapa M; Chen RE; Case JB; Amanat F; Rauseo AM; Haile A; Xie X; Klebert MK; Suessen T; Middleton WD; Shi PY; Krammer F; Teefey SA; Diamond MS; Presti RM; Ellebedy AH Nature; 2021 Aug; 596(7870):109-113. PubMed ID: 34182569 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses. Mo C; Li X; Wu Q; Fan Y; Liu D; Zhu Y; Yang Y; Liao X; Zhou Z; Zhou L; Li Q; Zhang Q; Liu W; Zhou R; Tian X Vaccine; 2023 Nov; 41(46):6863-6869. PubMed ID: 37821314 [TBL] [Abstract][Full Text] [Related]
36. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Lei H; Alu A; Yang J; He C; Hong W; Cheng Z; Yang L; Li J; Wang Z; Wang W; Lu G; Wei X Signal Transduct Target Ther; 2020 Dec; 5(1):291. PubMed ID: 33311439 [No Abstract] [Full Text] [Related]
37. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X Front Immunol; 2021; 12():771242. PubMed ID: 34880867 [TBL] [Abstract][Full Text] [Related]
38. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. Wisnewski AV; Liu J; Lucas C; Klein J; Iwasaki A; Cantley L; Fazen L; Campillo Luna J; Slade M; Redlich CA PLoS One; 2022; 17(1):e0262657. PubMed ID: 35041700 [TBL] [Abstract][Full Text] [Related]